Revenue Update on Acorda Therapeutics Inc(NASDAQ:ACOR)

Acorda Therapeutics Inc(NASDAQ:ACOR) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Jul 28, 2016. Company reported revenue of $127.46M. Analysts estimated a revenue of $128.10M. Earnings per share were $0.07. Analysts had estimated an EPS of $0.19.

Acorda Therapeutics Inc (ACOR) made into the market gainers list on Thursdays trading session with the shares advancing 0.36% or 0.09 points. Due to strong positive momentum, the stock ended at $24.99, which is also near the day’s high of $25.3999. The stock began the session at $25 and the volume stood at 4,47,565 shares. The 52-week high of the shares is $43.63 and the 52 week low is $23.85. The company has a current market capitalization of $1,151 M and it has 4,60,67,276 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Jun 24, 2016, David Lawrence (Chief of Business Operations) sold 500 shares at $25.09 per share price.Also, On Jun 10, 2016, Steven M Rauscher (director) sold 1,086 shares at $27.83 per share price.On May 16, 2016, Andrew A. Hindman (Chief Business Dev. Officer) sold 4,860 shares at $26.11 per share price, according to the Form-4 filing with the securities and exchange commission.

Acorda Therapeutics Inc. is a biopharmaceutical company engaged in the identification development and commercialization of therapies that restore neurological function and treat patients with neurological disorders. The Company’s markets three United States Food and Drug Administration (FDA)-approved therapies including Ampyra (dalfampridine) Extended Release Tablets 10milligrams a treatment to improve walking in patients with multiple sclerosis (MS). It also markets Zanaflex Capsules and tablets FDA-approved as short-acting drugs for the management of spasticity and Qutenza an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia also known as post-shingles pain. The Company is also developing a number of clinical and preclinical stage therapies for the treatment of a range of disorders including chronic post-stroke walking deficits (PSWD) Parkinson’s disease epilepsy heart failure MS and spinal cord injury.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *